Editas Medicine (NASDAQ: EDIT) reported Q1 EPS of ($0.76), $0.13 worse than the analyst estimate of ($0.63). Revenue for the quarter came in at $1.14 million versus the consensus estimate of $10.99 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.